DOCSLIB.ORG

©Ferrata Storti Foundation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
©Ferrata Storti Foundation scientific correspondence 327 ance was excellent and hematologic and non-hema- and G-CSF. Br J Haematol 1996; 93: 863-8. tologic toxicities were milder than with the ICE regi- 6. Chalmers EA, Franklin IM, Kelsey SM, et al. Treatment men. Moreover, days of neutropenic fever, hospital- of chronic myeloid leukaemia in first chronic phase ization and consumption of antibiotics were reduced. with idarubicin and cytarabine: mobilization of Phila- delphia-negative peripheral blood stem cells. Br J Unfortunately, no cytogenetic response was obtained. Haematol 1997; 96: 627-34. To date the patient has been transplanted with full 7. Carella AM, Cunningham I, Lerma E, et al. Mobiliza- engraftment and no major complications. tion and transplantation of Philadelphia-negative Several factors have been associated with the abil- peripheral-blood progenitor cells early in chronic myel- ity and capacity to mobilize hemopoietic progenitor ogenous leukemia. J Clin Oncol 1997; 15:1575-82. cells in CML such as intensity and type of chemo- 8. Mehta J, Mijovic A, Powles R, et al. Myelosuppressive therapy, time from diagnosis, phase of the disease chemotherapy to mobilize normal stem cells in chron- and previous treatment with IFN-␣.3-8 Our patient ic myeloid leukemia. Bone Marrow Transplant 1996; had several of these bad prognostic factors in both 17:25-9. 9. Carella AM, Lerma E, Celesti L, et al. Effective mobi- mobilization attempts. Although more intensive lization of Philadelphia-chromosome-negative cells in chemotherapy regimens have been associated with chronic myelogenous leukaemia patients using a less better mobilization, in our patient, the milder mini- intensive regimen. Br J Haematol 1998; 100:445-8. ICE regimen was associated with successful mobi- 10. Sureda A, Petit J, Brunet S, et al. Mini-ICE regimen as lization and with milder hematologic and non-hema- mobilization therapy for chronic myelogenous tologic toxicities. A similar observation has been leukaemia patients at diagnosis. Bone Marrow Trans- recently reported.9,10 Furthermore, the mini-ICE reg- plant 1999; 24:1285-90. imen showed no difference in terms of cytogenetic response or progenitor yield when compared with the ICE regimen.9,10 Although additional patients are nec- Lamivudine for the prevention of hepatitis B essary to confirm our data, they suggest that a sec- ond attempt to mobilize progenitor hemopoietic cells virus reactivation during autologous stem cell using the well-tolerated mini-ICE regimen should be transplantation. A case report tried in patients who have failed to get benefit from other intensive chemotherapy regimens. Reactivation of hepatitis B virus (HBV) is a fre- quent complication during chemotherapy; it may Antonio Salar, Anna Sureda, Bárbara Menéndez, Jorge Sierra give rise to hepatitis, hepatic failure and death and Clinical Hematology Division, may prevent further chemotherapy from being Hospital de la Santa Creu i Sant Pau, Barcelona, Spain administered. We present a case in which the use of lamivudine allowed autologous stem cell trans- plantation to be performed after a hepatitis flare- Key words up, suggesting a possible role for this drug in pre- Chronic myelogenous leukemia, mini-ICE regimen, ICE venting HBV reactivation during chemotherapy. regimen, mobilization, peripheral blood progenitor cells. Sir, Correspondence Hepatitis B virus (HBV) reactivation following chemotherapy withdrawal may result in hepatitis, Antonio Salar, M.D., Clinical Hematology Division, Hos- 1,2 pital de la Santa Creu i Sant Pau, Sant Antoni Maria i Claret hepatic failure and death. In fact, immunosup- pressive therapy leads to enhanced viral replication 167, 08025 Barcelona, Spain. and to an increased number of infected hepatocytes. Phone: international +34-93-2919396 – Fax: Interna- Withdrawal of the drugs results in partial restoration tional +34-93-2919466 – E-mail: [email protected] of immunocompetence with subsequent rapid destruction of hepatocytes.1 It was recently reported that nucleoside analogs such as lamivudine (a reverse References transcriptase inhibitor approved for the therapy of HIV infection) is effective in suppressing HBV repli- 1. McGlave PB, De Fabritiis P, Deisseroth A, et al. Autol- cation by incorporation of its monophosphate form ogous transplants for chronic myelogenous leukaemia; 3 results from eight transplant groups. Lancet 1994; into DNA, which results in chain termination. 343:1486-8. We report the case of a 40-year old male, known to 2. O’Brien SG, Goldman JM. Autografting in chronic be HBsAg positive for 17 years, without any signs of myeloid leukaemia. Blood Rev 1994; 8:63-9. active hepatitis, who was diagnosed as having mantle 3. Carella AM, Podestá M, Frassoni F, et al. Collection of cell lymphoma (MCL) stage IIIA, in March 1997. He “normal” blood repopulating cells during early hemo- was treated with six cycles of chemotherapy according poietic recovery after intensive conventional chemo- to the F-MACHOP protocol4 between March and July therapy in chronic myelogenous leukemia. Bone Mar- 1997, without any complications. row Transplant 1993; 12:267-71. Thirty days after the end of chemotherapy he pre- 4. Boqué C, Petit J, Sarrá J, et al. Mobilization of periph- eral stem cells with intensive chemotherapy (ICE regi- sented the full clinical picture of an acute hepatitis, men) and G-CSF in chronic myeloid leukemia. Bone with SGOT at 2,820 U/L, SGPT at 1,525 U/L and Marrow Transplant 1996; 18:879-84. total bilirubin at 14 mg/dL. 5. Johnson RJ, Owen RG, Chiold JA, et al. Mobilization of HBV-DNA (detected by nested polymerase chain Philadelphia-negative peripheral blood mononuclear reaction as described by Kaneko et al.5) was positive cells in chronic myeloid leukaemia using hydroxyurea (having been negative before starting chemothera- Haematologica vol. 85(3):March 2000 328 scientific correspondence Figure 1. Clinical course and main laboratory data of the patient. Dx = diagnosis. end CHT = end of chemotherapy ( 6 cycles of F-MACHOP). PBSC = peripheral blood stem cell harvest after G-CSF priming. ASCT = autologous stem cell transplantation after conditioning with BAVC. py). The patient recovered spontaneously in 70 days. tive therapeutic option in HBsAg positive patients HBV-DNA was negative by day 90. needing chemotherapy and transplantation. In accordance with our protocol for MCL,6 he This drug was recently shown to be superior to underwent G-CSF-primed peripheral blood stem cell famciclovir in terms of HBV-DNA reduction and harvest and was then started on lamivudine 100 response in the treatment of chronic hepatitis B,7 mg/daily, with the purpose of preventing HBV reac- and also to be effective in the prevention of graft tivation during the procedure of autotransplant. After infection following liver transplantation.8 The opti- being on lamivudine for twenty days, he was condi- mal duration of therapy after transplantation has not tioned with BAVC and reinfused with 5.2ϫ106 CD34 been established yet, on the one hand it should be cells/kg b.w. kept long enough to prevent HBV relapses, on the He reached an ANC of 500/µL at day +10 and other hand it should be suspended quite rapidly to 1,000/µL at day +11; a Plt count of 20,000/µL at day avoid the development of resistance due to muta- +12 and of 50,000/µL at day +13; he needed 3 Plt tions. We suggest that administration of lamividine aphereses and 8 administrations of G-CSF and was for four to six months after the last chemotherapy treated with antibiotic therapy for a Gram-positive administered accomplishes these needs. sepsis. He was then discharged from the hospital on To our knowledge, no other cases of prophylactic day +14 and was maintained on lamivudine for 6 lamivudine therapy in patients with HBV infection months afterwards. undergoing autologous stem cell transplantation During this period he was regularly monitored with have been reported so far. Thus the case herein twice-monthly blood counts, transaminase levels and described indicates a possible role for lamivudine in HBV-DNA: all these parameters remained normal/ne- preventing HBV reactivation during antineoplastic gative throughout the period. chemotherapy. Currently, 28 months from diagnosis and 20 Federico Silvestri, Alessandra Sperotto, Anna Ermacora, months from transplant, the patient is in complete Renato Fanin, Daniela Damiani, Michele Baccarani remission, with normal liver function tests and HBV- DNA negative. Division of Hematology and Department of Bone Marrow HBV reactivation may represent a potentially harm- Transplantation, University Hospital, Udine, Italy ful problem during administration of chemotherapy, particularly high-dose chemotherapy, and in some Key words patients prevents transplantation. Therefore treat- Lamivudine, hepatitis B virus, autologous stem cell trans- ment for prevention of HBV reactivation is needed to plantation. protect HBV carriers against chemotherapy-induced hepatic failure. Funding Since lamivudine is devoid of side effects, particu- This work was supported by AIL 30 ore per la vita and larly those on hemopoiesis, it seeems to be an effec- Treviso AIL, Italy. Haematologica vol. 85(3):March 2000 scientific correspondence 329 Correspondence py (ECP), which consists of sensitization of peripheral Federico Silvestri, M.D., Division of Hematology, Univer- leukocytes by 8-methoxy-psoralen (8-MOP) and sity Hospital, p.le S. Maria della Misericordia, 33100 Udine, extracorporeal exposure of leukeapheresis collections Italy. Phone: international +39-0432-559662 – Fax: inter- to UVA.1-4 national +39-0432-559661 – E-mail: ematologia@drm- We describe two pediatric patients successfully mm.uniud.it treated with ECP for severe persistent cGvHD after many years of ineffective immunosuppression. References Case #1. A 14-year old girl transplanted for acute lymphoblastic leukemia from her HLA-identical 1. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chron- brother in 1988, developed progressive refractory ic hepatitis B virus infection following withdrawal of cGvHD, which subsequently involved the skin (lichen- chemotherapy in lymphoma patients. Q J Med 1989; planus-like papulae, scleroderma, diffuse alopecia), 73:911-7.
Load more

Recommended publications
  • Idamycin PFS® Idarubicin Hydrochloride Injection
    Idamycin PFS® idarubicin hydrochloride injection Rx only FOR INTRAVENOUS USE ONLY WARNINGS 1. IDAMYCIN PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of IDAMYCIN PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre- existing cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs when IDAMYCIN PFS is used at effective therapeutic doses. 4. It is recommended that IDAMYCIN PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi- synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12-Naphthacenedione, 9-acetyl-7-[(3- amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11- trihydroxyhydrochloride, (7S-cis). The structural formula is as follows: C26 H27 NO9 .HCL M.W. 533.96 1 Reference ID: 3668307 IDAMYCIN PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.
    [Show full text]
  • Idarubicin.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrIDARUBICIN idarubicin hydrochloride injection Preservative Free Solution, 1 mg/mL, intravenous injection Antineoplastic Agent Pfizer Canada ULC Date of Initial Authorization: 17,300 Trans-Canada Highway July 30, 2013 Kirkland, Quebec, H9J 2M5 Date of Revision: September 14, 2021 Submission Control Number: 255782 ©Pfizer Canada ULC, 2021 IDARUBICIN (idarubicin hydrochloride injection) Page 1 of 31 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Cardiovascular JA/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................2 TABLE OF CONTENTS ............................................................................................................2 1 INDICATIONS.............................................................................................................4 1.1 Pediatrics .................................................................................................................4 1.2 Geriatrics..................................................................................................................4 2 CONTRAINDICATIONS................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...........................................................5 4 DOSAGE AND ADMINISTRATION................................................................................5
    [Show full text]
  • Summary Attachment for Eudract
    Avenue E. Mounier 83/11 1200 Brussels Belgium Tel: +32 2 774 1611 Email: [email protected] www.eortc.org Summary Attachment for EudraCT Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Title of the Study Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial) Investigators & Study Centers Number of Country City patients Belgium 4 101.Hopital Jules Bordet (BE) Brussels 1 109.A.Z. St Jan (BE) Brugge 3 Italy 28 3931.Tor Vergata Roma (IT) Roma 12 733.La Sapienza Ematologia (IT) Roma 16 Netherlands 43 304.RU Nijmegen (NL) Nijmegen 24 310.Univ Med Ctr Leiden (NL) Leiden 13 22.J Bosch 'S Hertogenb (NL) 's-Hertogenbosch 6 Grand Total 75 ST-006-AF-01 Page 1 of 4 Template version 2 Short Study Report for Health Authorities EORTC Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Publication Willemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, (reference) Vignetti M, Amadori S, de Witte T, Marie JP.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • How I Treat How I Treat Hyperleukocytosis in Acute Myeloid Leukemia
    From www.bloodjournal.org by guest on January 2, 2016. For personal use only. How I Treat How I treat hyperleukocytosis in acute myeloid leukemia Christoph R¨olligand Gerhard Ehninger Medizinische Klinik und Poliklinik I, Universit¨atsklinikumder Technischen Universit¨at Dresden, Germany Hyperleukocytosis (HL) per se is a labora- chronic leukemias, and particularly leuko- lactate dehydrogenase as an indicator for tory abnormality, commonly defined by stasis occurs more often in acute myeloid high proliferation are part of prognostic a white blood cell count >100 000/mL, leukemia (AML) for several reasons. Only scores guiding risk-adapted consolidation caused by leukemic cell proliferation. Not a small proportion of AML patients present strategies, HL at initial diagnosis must be the high blood count itself, but complica- with HL, but these patients have a partic- considered a hematologic emergency and tions such as leukostasis, tumor lysis syn- ularly dismal prognosis because of (1) a requires rapid action of the admitting drome, and disseminated intravascular higher risk of early death resulting from physician in order to prevent early death. coagulation put the patient at risk and HL complications; and (2) a higher proba- (Blood. 2015;125(21):3246-3252) require therapeutic intervention. The risk bility of relapse and death in the long run. of complications is higher in acute than in Whereas initial high blood counts and high Incidence and pathophysiology In untreated acute myeloid leukemia (AML), ;5% to 20% of patients factor VII.18 TLS may occur as a result of spontaneous or treatment- present with hyperleukocytosis (HL).1-10 In a patient with HL, under- induced cell death.
    [Show full text]
  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
    LEUKEMIA TREATMENT REGIMENS: Acute Lymphoblastic Leukemia (ALL) (Part 1 of 12) Note: The National Comprehensive Cancer Network (NCCN) Guidelines® for Acute Lymphoblastic Leukemia (ALL) should be consulted for the management of patients with lymphoblastic lymphoma. Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. They are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any
    [Show full text]
  • (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1
    (CANCER RESEARCH 48, 5348-5352. September 15. 1988] Phase I Clinical Trial of Orally Administered 4-Demethoxydaunorubicin (Idarubicin) with Pharmacokinetic and in Vitro Drug Sensitivity Testing in Children with Refractory Leukemia1 Ching-Hon Pui,2 Siebold S. N. de Graaf,3 Lois W. Dow, John H. Rodman, William E. Evans, Bruce S. Alpert, and Sharon B. Murphy Departments ofHematology and Oncology [C-H. P., L. W. D., S. B. M.] and Pharmaceutical Division [S. S. N. d. G., J. H. R., W. E. E.], St. Jude Children's Research Hospital, and Divisions of Hematology-Oncology [C-H. P., L. W. D., S. B. M.] and Cardiology [B. S. A.], Department of Pediatrics, University of Tennessee, Memphis, College of Medicine, Memphis, Tennessee 38101 ABSTRACT than that of analogues or i.v. idarubicin (9, 16). However, nausea and vomiting were generally more severe in patients Fifteen children with acute leukemia in relapse, refractory to conven receiving oral idarubicin (16). As a single agent in adults, oral tional therapy, were treated with idarubicin administered orally for 3 consecutive days in dosages ranging from 30 to 50 mg/m2 per day at 19- idarubicin has antileukemic activity at dosages of 45 to 90 mg/ m2 distributed over 3 consecutive days (9, 17, 18). Very little to 21-day intervals. Gastrointestinal complications, including nausea, vomiting, abdominal pain, diarrhea and stomatitis, were the major forms information is available for oral idarubicin treatment in children of dose-limiting toxicity, affecting the majority of patients at all levels of with leukemia. We report here the results of Phase I clinical, idarubicin dosage.
    [Show full text]
  • S4 Acute Myeloid Leukaemia
    Haematology Cancer Clinical Guidelines Haematology Expert Advisory Group (EAG) on behalf of Northern Cancer Alliance Title: Haematology Cancer Clinical Guidelines Authors: Haematology EAG Circulation List: As detailed on page 2 Contact Details: Mrs C McNeill, Senior Administrator, Cancer Alliance Telephone: 01138252976 Version History: Date: 10.04.18 Version: V17-section 4 Review Date: November 2019 Document Control Version Date Summary Review Date V17 Date Agreed: Haematology EAG members agreed the Guidelines on: Emailed to group on 12.04.18, for formal endorsement at the next meeting. Review Date: November 2019 1 CONTENTS SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML) SECTION 5 Guidelines for Management of Myelodysplastic Syndromes SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia SECTION 8 Guidelines for Management of Myeloproliferative Disorders Polycythaemia Vera (PRV) Myelofibrosis (MF) SECTION 9 Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders Hairy Cell Leukaemia T-Prolymphocytic Leukaemia Waldenstrom Macroglobulinaemia SECTION 10 Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma Mantle Cell Lymphoma SECTION 11 Guidelines for the Management
    [Show full text]
  • CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
    CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS1 CYTOTOXIC HAZARDOUS MEDICATIONS NON-CYTOTOXIC HAZARDOUS MEDICATIONS Altretamine IDArubicin Acitretin Iloprost Amsacrine Ifosfamide Aldesleukin Imatinib 3 Arsenic Irinotecan Alitretinoin Interferons Asparaginase Lenalidomide Anastrazole 3 ISOtretinoin azaCITIDine Lomustine Ambrisentan Leflunomide 3 azaTHIOprine 3 Mechlorethamine Bacillus Calmette Guerin 2 Letrozole 3 Bleomycin Melphalan (bladder instillation only) Leuprolide Bortezomib Mercaptopurine Bexarotene Megestrol 3 Busulfan 3 Methotrexate Bicalutamide 3 Methacholine Capecitabine 3 MitoMYcin Bosentan MethylTESTOSTERone CARBOplatin MitoXANtrone Buserelin Mifepristone Carmustine Nelarabine Cetrorelix Misoprostol Chlorambucil Oxaliplatin Choriogonadotropin alfa Mitotane CISplatin PACLitaxel Cidofovir Mycophenolate mofetil Cladribine Pegasparaginase ClomiPHENE Nafarelin Clofarabine PEMEtrexed Colchicine 3 Nilutamide 3 Cyclophosphamide Pentostatin cycloSPORINE Oxandrolone 3 Cytarabine Procarbazine3 Cyproterone Pentamidine (Aerosol only) Dacarbazine Raltitrexed Dienestrol Podofilox DACTINomycin SORAfenib Dinoprostone 3 Podophyllum resin DAUNOrubicin Streptozocin Dutasteride Raloxifene 3 Dexrazoxane SUNItinib Erlotinib 3 Ribavirin DOCEtaxel Temozolomide Everolimus Sirolimus DOXOrubicin Temsirolimus Exemestane 3 Tacrolimus Epirubicin Teniposide Finasteride 3 Tamoxifen 3 Estramustine Thalidomide Fluoxymesterone 3 Testosterone Etoposide Thioguanine Flutamide 3 Tretinoin Floxuridine Thiotepa Foscarnet Trifluridine Flucytosine Topotecan Fulvestrant
    [Show full text]
  • Acute Myeloid Leukemia (AML) Treatment Regimens
    Acute Myeloid Leukemia (AML) Treatment Regimens Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. uInduction Therapy1 Note: All recommendations are Category 2A unless otherwise indicated. The NCCN believes the best option for any patient with cancer is in a clinical trial and strongly encourages this option for all patients. PATIENT CRITERIA REGIMEN AND DOSING Age <60 years2-8 Days 1–3: An anthracycline (daunorubicin 60–90mg/m2 IV OR idarubicin 12mg/m2) Days 1–7: Cytarabine 100–200mg/m2 continuous IV (Category 1).
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
    cells Review Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Jan Philipp Bewersdorf and Amer M. Zeidan * Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, PO Box 208028, New Haven, CT 06520-8028, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-203-737-7103; Fax: +1-203-785-7232 Received: 19 September 2020; Accepted: 15 October 2020; Published: 17 October 2020 Abstract: Up to 18% of patients with acute myeloid leukemia (AML) present with a white blood cell (WBC) count of greater than 100,000/µL, a condition that is frequently referred to as hyperleukocytosis. Hyperleukocytosis has been associated with an adverse prognosis and a higher incidence of life-threatening complications such as leukostasis, disseminated intravascular coagulation (DIC), and tumor lysis syndrome (TLS). The molecular processes underlying hyperleukocytosis have not been fully elucidated yet. However, the interactions between leukemic blasts and endothelial cells leading to leukostasis and DIC as well as the processes in the bone marrow microenvironment leading to the massive entry of leukemic blasts into the peripheral blood are becoming increasingly understood. Leukemic blasts interact with endothelial cells via cell adhesion molecules such as various members of the selectin family which are upregulated via inflammatory cytokines released by leukemic blasts. Besides their role in the development of leukostasis, cell adhesion molecules have also been implicated in leukemic stem cell survival and chemotherapy resistance and can be therapeutically targeted with specific inhibitors such as plerixafor or GMI-1271 (uproleselan).
    [Show full text]